Annamaria Siggillino

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola et al. · Journal of Thoracic Oncology · 2011 · 179 citations · Full text

Medicine, Oncology, Pharmacology +14

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Giulio Metro, Rita Chiari, Simona Duranti et al. · Lung Cancer · 2012 · 70 citations

Medicine, Molecular Genetics, Oncology +16

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

Vienna Ludovini, Irene Floriani, Lorenza Pistola et al. · Journal of Thoracic Oncology · 2011 · 59 citations

Medicine, Genetics, Oncology +14

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for <i>KRAS</i> mutant tumors

Elisa Baldelli, Guido Bellezza, Eric B. Haura et al. · Oncotarget · 2015 · 42 citations · Full text

Medicine, Cancer Biology, Oncology +17

Dyskerin and TERC expression may condition survival in lung cancer patients

Marianna Penzo, Vienna Ludovini, Davide Treré et al. · Oncotarget · 2015 · 40 citations · Full text

Medicine, Oncology, Pathology +11